Investigating Natalizumab Through Further Observational Research and Monitoring

Conditions:		Crohn's Disease
Purpose:		The purpose of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events in patients with Crohn's Disease(CD) treated with TYSABRI® (Natalizumab)
Study Summary:
Criteria:		Inclusion Criteria: - CD patients prescribed TYSABRI® within the TOUCH prescribing program must be enrolled prior to their 6th infusion of TYSABRI® Exclusion Criteria:
NCT ID:		NCT00707512
Primary Contact:		N/A
Backup Contact:		N/A
Location Contact:		Morgantown, West Virginia 26505 United States Contact Phone: 888-613-7542 Email: LSKC_CD_INFORM@unitedbiosource.com Site Status: Recruiting

Data Source:		ClinicalTrials.gov
Date Processed:		May 20, 2013
Modifications to this listing:		Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"

First Name:

Last Name:

Email Address:

Confirm Email:

Daytime Phone (eg. 555-555-5555):

City:

State:

Zip Code:

Best Time to Call:

Morning	Afternoon	Evening
Please contact me by email instead of calling.

Questions/Comments:

I have read and agree with the Privacy Policy

I have reviewed the eligibility criteria and believe I am eligible for this clinical trial

I would like to be notified about new clinical trials.

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.